Arterial hypertension and cancer

International Journal of Cancer

Volumn 134, Issue 10, 2014, Pages 2269-2277

  Milan, Alberto ^a   Puglisi, Elisabetta ^a   Ferrari, Laura ^b   Bruno, Giulia ^a   Losano, Isabel ^a   Veglio, Franco ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Department of Medical Oncology Spedali Civili ^*  (Italy)

Author keywords

anti VEGF drugs; antihypertensive therapies; arterial hypertension; cancer therapies

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; VASCULOTROPIN ANTIBODY;

BLOOD PRESSURE; CANCER CHEMOTHERAPY; CANCER RISK; CARCINOGENESIS; CARDIOVASCULAR RISK; COMORBIDITY; DISEASE ASSOCIATION; HUMAN; HYPERTENSION; NEOPLASM; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANTI VEGF DRUGS; ANTIHYPERTENSIVE THERAPIES; ARTERIAL HYPERTENSION; CANCER THERAPIES;

ANTIHYPERTENSIVE AGENTS; ANTINEOPLASTIC AGENTS; HUMANS; HYPERTENSION; NEOPLASMS; RISK ASSESSMENT; RISK FACTORS;

EID: 84895919716     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28334     Document Type: Review

References (82)

1. Colt JS, Schwartz K, Graubard BI, et al. Hypertension and risk of renal cell carcinoma among white and black americans. Epidemiology 2011; 22: 797-804
2. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434
3. Gurevich F, Perazella MA,. Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med 2009; 122: 322-8.
4. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
5. Izzedine H, Massard C, Spano JP, et al. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 2010; 46: 439-48.
6. Azizi M, Chedid A, Oudard S,. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 2008; 358: 95-7.
7. Nazer B, Humphreys BD, Moslehi J,. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation 2011; 124: 1687-91.
8. Kiriakidis S, Andreakos E, Monaco C, et al. VEGF expression in human macrophages is NF-kappaB-dependent: studies using adenoviruses expressing the endogenous NF-kappaB inhibitor IkappaBalpha and a kinase-defective form of the IkappaB kinase 2. J Cell Sci 2003; 665: 1253-8767.
9. Carmeliet P, Ruiz de Almodovar P. VEGF ligands and receptors: implications in neurodevelopment and neurodegeneration. Cell Mol Life Sci 2013; 70: 1763-7.
10. Hayman SR, Leung N, Grande JP, et al. VEGF inhibition, hypertension, and renal toxicity. Curr Oncol Rep 2012; 14: 285-94.
11. Zerbini G, Lorenzi M, Palini A., Tumor angiogenesis. N Engl J Med 2008; 359: 763; author reply 764.
12. Mourad JJ, des Guetz G, Debbabi H, et al. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 2008; 19: 927-34.
13. Steeghs N, Gelderblom H, Roodt JO, et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res 2008; 14: 3470-6.
14. Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with bay 43-9006. J Clin Oncol 2006; 24: 1363-9.
15. Facemire CS, Nixon AB, Griffiths R, et al. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 2009; 54: 652-8.
16. Keefe D, Bowen J, Gibson R, et al. Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. Oncologist 2011; 16: 432-444.
17. Kappers MH, van Esch JH, Sluiter W, et al. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 2010; 56: 675-81.
18. Zhu X, Wu S, Dahut WL, et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007; 49: 186-93.
19. Piccirillo JF, Tierney RM, Costas I, et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004; 291: 2441-7.
20. Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the european society of hypertension (ESH) and of the European society of cardiology (ESC). J Hypertens 2007; 25: 1105-87.
21. Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102: 596-604.
22. Lenfant C, Chobanian AV, Jones DW, et al. Seventh report of the joint national committee on the prevention, detection, evaluation, and treatment of high blood pressure (JNC 7): resetting the hypertension sails. Hypertension 2003; 41: 1178-9.
23. Jain M, Townsend RR,. Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr Hypertens Rep 2007; 9: 320-8.
24. Colt JS, Schwartz K, Graubard BI, et al. Hypertension and risk of renal cell carcinoma among white and black Americans. Epidemiology 2011 22: 797-804.
25. Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol 2011; 12: 65-82.
26. Mason RP,. Calcium channel blockers, apoptosis and cancer: is there a biologic relationship? J Am Coll Cardiol 1999; 34: 1857-66.
27. Santoni G, Santoni M, Nabissi M,. Functional role of t-type calcium channels in tumour growth and progression: prospective in cancer therapy. Br J Pharmacol 2012; 166: 1244-6.
28. Sezzi ML, De Luca G, Materazzi M, et al. Effects of a calcium-antagonist (flunarizine) on cancer cell movement and phagocytosis. Anticancer Res 1985; 5: 265-271.
29. Lijinsky W, Reuber MD,. Pathologic effects of chronic administration of hydrochlorothiazide, with and without sodium nitrite, to F344 rats. Toxicol Ind Health 1987; 3: 413-422.
30. Kunert-Radek J, Stepien H, Radek A, et al. Inhibitory effect of calcium channel blockers on proliferation of human glioma cells in vitro. Acta Neurol Scand 1989; 79: 166-9.
31. Mickisch GH, Kossig J, Keilhauer G, et al. Effects of calcium antagonists in multidrug resistant primary human renal cell carcinomas. Cancer Res 1990; 50: 3670-4.
32. Pahor M, Guralnik JM, Salive ME, et al. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996; 9: 695-9.
33. Grossman E, Messerli FH, Goldbourt U,. Carcinogenicity of cardiovascular drugs. Curr Hypertens Rep 1999; 1: 212-8.
34. Jick H, Jick S, Derby LE, et al. Calcium-channel blockers and risk of cancer. Lancet 1997; 349: 525-8.
35. Ahr HJ, Bomhard E, Enzmann H, et al. Calcium channel blockers and the risk of cancer: a preclinical assessment. Cardiovasc Drugs Ther 1998; 12: 157-69.
36. Jonas M, Goldbourt U, Boyko V, et al. Nifedipine and cancer mortality: ten-year follow-up of 2607 patients after acute myocardial infarction. Cardiovasc Drugs Ther 1998; 12: 177-81.
37. Michels KB, Rosner BA, Walker AM, et al. Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of u.S. Women: the nurses' health study. Cancer 1998; 83: 2003-7.
38. Trenkwalder P, Hendricks P, Hense HW,. Treatment with calcium antagonists does not increase the risk of fatal or non-fatal cancer in an elderly mid-european population: results from STEPHY II. Starnberg study on epidemiology of parkinsonism and hypertension in the elderly. J Hypertens 1998; 16: 1113-6.
39. Shapiro JA, Williams MA, Weiss NS, et al. Hypertension, antihypertensive medication use, and risk of renal cell carcinoma. Am J Epidemiol 1999; 149: 521-30.
40. Corrao G, Scotti L, Bagnardi V, Sega R,. Hypertension, antihypertensive therapy and renal-cell cancer: a meta-analysis. Curr Drug Saf 2007; 2: 125-33.
41. Weinmann S, Glass AG, Weiss NS, et al. Use of diuretics and other antihypertensive medications in relation to the risk of renal cell cancer. Am J Epidemiol 1994; 140: 792-804.
42. Grossman E, Messerli FH, Goldbourt U,. Does diuretic therapy increase the risk of renal cell carcinoma? Am J Cardiol 1999; 83: 1090-3.
43. Flaherty KT, Fuchs CS, Colditz GA, et al. A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States). Cancer Causes Control 2005; 16: 1099-106.
44. Setiawan VW, Stram DO, Nomura AM, et al. Risk factors for renal cell cancer: the multiethnic cohort. Am J Epidemiol 2007; 166: 932-40.
45. Ellison DH, Loffing J,. Thiazide effects and adverse effects: insights from molecular genetics. Hypertension 2009; 54: 196-202.
46. Jensen AO, Thomsen HF, Engebjerg MC, et al. Use of photosensitising diuretics and risk of skin cancer: a population-based case-control study. Br J Cancer 2008; 99: 1522-8.
47. Ruiter R, Visser LE, Eijgelsheim M, et al. High-ceiling diuretics are associated with an increased risk of basal cell carcinoma in a population-based follow-up study. Eur J Cancer 2010; 46: 2467-72.
48. Coleman CI, Baker WL, Kluger J, et al. Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials. J Hypertens 2008; 26: 622-9.
49. Mitchell AB,. Mrc trial of treating hypertension in older adults. BMJ 1992; 304:1631; author reply 1631-1632
50. Zavanella T, Radaelli G, Girotti P, et al. Evaluation of the tumor-promoting activity of two beta-adrenoreceptor blocking agents, propranolol and atenolol, in liver of fischer 344 rats. Carcinogenesis 1994; 15: 2531-9.
51. Singh A, Bangalore S,. Which, if any, antihypertensive agents cause cancer? Curr Opin Cardiol 2012; 27: 374-80.
52. Schuller HM, Cole B,. Regulation of cell proliferation by beta-adrenergic receptors in a human lung adenocarcinoma cell line. Carcinogenesis 1989; 10: 1753-5.
53. Cole SW, Sood AK,. Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res 2012; 18: 1201-6.
54. Meier CR, Derby LE, Jick SS, et al. Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch Intern Med 2000; 160: 349-53.
55. Li CI, Malone KE, Weiss NS, et al. Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65-79 years. Cancer 2003; 98: 1504-13.
56. Assimes TL, Elstein E, Langleben A, et al. Long-term use of antihypertensive drugs and risk of cancer. Pharmacoepidemiol Drug Saf 2008; 17: 1039-49.
57. Jansen L, Below J, Chang-Claude J, et al. Beta blocker use and colorectal cancer risk: population-based case-control study. Cancer, 2012; 118: 3911-9.
58. Drell TL, Joseph J, Lang K, et al. Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat 2003; 80: 63-70.
59. Masur K, Niggemann B, Zanker KS, et al. Norepinephrine-induced migration of sw 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res 2001; 61: 2866-9.
60. Park PG, Merryman J, Orloff M, et al. Beta-adrenergic mitogenic signal transduction in peripheral lung adenocarcinoma: implications for individuals with preexisting chronic lung disease. Cancer Res 1995; 55: 3504-8.
61. Yang EV, Sood AK, Chen M, et al. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res 2006; 66: 10357-64.
62. Sood AK, Bhatty R, Kamat AA, et al. Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res 2006; 12: 369-75.
63. Zhang D, Ma Q, Shen S, et al. Inhibition of pancreatic cancer cell proliferation by propranolol occurs through apoptosis induction: the study of beta-adrenoceptor antagonist's anticancer effect in pancreatic cancer cell. Pancreas 2009; 38: 94-100.
64. Guo K, Ma Q, Wang L, et al. Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol. Oncol Rep 2009; 22: 825-30.
65. Zhang D, Ma QY, Hu HT, et al. Beta2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting creb, nfkappab and ap-1. Cancer Biol Ther 2010; 10: 19-29.
66. Liao X, Che X, Zhao W, et al. The beta-adrenoceptor antagonist, propranolol, induces human gastric cancer cell apoptosis and cell cycle arrest via inhibiting nuclear factor kappa -b signaling. Oncol Rep 2010; 24: 1669-76.
67. Pasquier E, Ciccolini J, Carre M, et al. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget 2011; 2: 797-809.
68. Powe DG, Voss MJ, Zanker KS, et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010; 1: 628-38.
69. Barron TI, Connolly RM, Sharp L, et al. Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol 2011; 29: 2635-44.
70. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 2011; 29: 2645-52.
71. Al-Wadei HA, Al-Wadei MH, Schuller HM,. Prevention of pancreatic cancer by the beta-blocker propranolol. Anticancer Drugs 2009; 20: 477-82.
72. De Giorgi V, Grazzini M, Gandini S, et al. Treatment with beta-blockers and reduced disease progression in patients with thick melanoma. Arch Intern Med 2011; 171: 779-81.
73. Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-i-converting enzyme protect against risk of cancer? Lancet 1998; 352: 179-84.
74. Wang Q, Lei X, Zhu S, et al. Angiotensin-I converting enzyme inhibitors suppress angiogenesis and growth of esophageal carcinoma xenografts. Dis Esophagus 2012; 25: 757-63.
75. Vinson GP, Barker S, Puddefoot JR,. The renin-angiotensin system in the breast and breast cancer. Endocrine Relat Cancer 2012; 19: R1-19.
76. Chae YK, Valsecchi ME, Kim J, et al. Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBS, and/or statins. Cancer Invest 2011; 29: 585-93.
77. Sipahi I, Chou J, Mishra P, et al. Meta-analysis of randomized controlled trials on effect of angiotensin-converting enzyme inhibitors on cancer risk. Am J Cardiol 2011; 108: 294-301.
78. Yoon C, Yang HS, Jeon I, et al. Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies. CMAJ 2011; 183: E1073-4.
79. Gallagher PE, Cook K, Soto-Pantoja D, et al. Angiotensin peptides and lung cancer. Curr Cancer Drug Target 2011; 11: 394-404.
80. Chappell MC,. Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS receptor axis: more than regulation of blood pressure? Hypertension 2007; 50: 596-9.
81. ARB Trialists Collaboration,. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens 2011; 29: 623-35.
82. Mancia G,. Angiotensin receptor antagonists and increased risk of cancer. Further evidence against. J Hypertens 2011; 29: 653-4.